ライフサイエンスコーパス: proliferative vitreoretinopathy

1 n several fibrotic diseases, in RPE cells in proliferative vitreoretinopathy.

2 g this pathway could be useful in preventing proliferative vitreoretinopathy.

3 s that involve RPE dedifferentiation such as proliferative vitreoretinopathy.

4 l diseases, such as diabetic retinopathy and proliferative vitreoretinopathy.

5 ation of fibroproliferative diseases such as proliferative vitreoretinopathy.

6 ted disease progression in a rabbit model of proliferative vitreoretinopathy.

7 l therapy for related human diseases such as proliferative vitreoretinopathy.

8 t of endophthalmitis, retinal detachment and proliferative vitreoretinopathy.

9 atment of retinal detachment associated with proliferative vitreoretinopathy.

10 inopathies, such as diabetic retinopathy and proliferative vitreoretinopathy.

11 y, and in nonvascular retinopathies, such as proliferative vitreoretinopathy.

12 lications for proliferative diseases such as proliferative vitreoretinopathy.

13 uld have implications in the pathogenesis of proliferative vitreoretinopathy.

14 occlusion with vitreous hemorrhage (1), and proliferative vitreoretinopathy (1).

15 ual failure of surgery is the development of proliferative vitreoretinopathy, accounting for the fail

16 ogic characteristics of patients who develop proliferative vitreoretinopathy after retinoblastoma tre

17 in pathogenesis of such retinal disorders as proliferative vitreoretinopathy and age-related macular

18 on in anomalous reparative processes such as proliferative vitreoretinopathy and as a laboratory tool

19 several epiretinal membranes associated with proliferative vitreoretinopathy and idiopathic epiretina

20 NF-kappaB may be a useful strategy to treat proliferative vitreoretinopathy and uveitis, ocular dise

21 inal breaks, failure to reattach the retina, proliferative vitreoretinopathy, and delayed reabsorptio

22 the rate of retinal redetachment by limiting proliferative vitreoretinopathy, and protect against pho

23 ns include antimetabolites for modulation of proliferative vitreoretinopathy, antimicrobial agents fo

24 Proliferative vitreoretinopathy developed in response to

25 Proliferative vitreoretinopathy did not develop in salin

26 repair recurrent retinal detachments due to proliferative vitreoretinopathy, focusing on the most re

27 ature of recurrent retinal detachment due to proliferative vitreoretinopathy has grown concomitantly

28 ithout vascular cell involvement, similar to proliferative vitreoretinopathy in humans.

29 tro model of the later contractile stages of proliferative vitreoretinopathy, interleukin-1 beta (IL-

30 Proliferative vitreoretinopathy is caused by the contrac

31 Recurrent retinal detachment complicated by proliferative vitreoretinopathy is now most frequently t

32 Complications consisted of proliferative vitreoretinopathy (n = 13), recurrent neov

33 lens status, tamponading agent, preoperative proliferative vitreoretinopathy (PVR) and axial length (

34 several epiretinal membranes associated with proliferative vitreoretinopathy (PVR) and idiopathic epi

35 ival, and contraction) that are intrinsic to proliferative vitreoretinopathy (PVR) and induce the dis

36 in vitro and in vivo models for experimental proliferative vitreoretinopathy (PVR) and provide a deta

37 Proliferative vitreoretinopathy (PVR) exemplifies a dise

38 t-derived growth factor (PDGF) contribute to proliferative vitreoretinopathy (PVR) in experimental mo

39 or (alphaPDGFR) is required for experimental proliferative vitreoretinopathy (PVR) in rabbits.

40 Proliferative vitreoretinopathy (PVR) is a blinding dise

41 Proliferative vitreoretinopathy (PVR) is a complication

42 Proliferative vitreoretinopathy (PVR) is a complication

43 Proliferative vitreoretinopathy (PVR) is a disorder char

44 Proliferative vitreoretinopathy (PVR) is a nonneovascula

45 Proliferative vitreoretinopathy (PVR) is a recurring and

46 Proliferative vitreoretinopathy (PVR) is a serious compl

47 Proliferative vitreoretinopathy (PVR) is a serious probl

48 Proliferative vitreoretinopathy (PVR) is characterized b

49 Proliferative vitreoretinopathy (PVR) is mediated by pro

50 Proliferative vitreoretinopathy (PVR) is the primary cau

51 TNF-alpha is widely expressed in proliferative vitreoretinopathy (PVR) membranes and is p

52 Proliferative vitreoretinopathy (PVR) occurs in approxim

53 To profile vitreous cytokine expression of proliferative vitreoretinopathy (PVR) patients.

54 us from patients with retinal detachment and proliferative vitreoretinopathy (PVR) plus vitreous from

55 Proliferative vitreoretinopathy (PVR) remains the most c

56 Retrospective review of three cases of proliferative vitreoretinopathy (PVR) that developed aft

57 Proliferative vitreoretinopathy (PVR) thwarts the repair

58 gher level 1 failure rates when grade 0 or B proliferative vitreoretinopathy (PVR) was present and hi

59 ibozyme to prevent or inhibit development of proliferative vitreoretinopathy (PVR) was tested in a di

60 h factor (PDGF) isoforms are associated with proliferative vitreoretinopathy (PVR), a sight-threateni

61 traction by ARPE-19 is an in vitro model for proliferative vitreoretinopathy (PVR), an aberrant wound

62 ermine the role of NF-kappaB in experimental proliferative vitreoretinopathy (PVR), and may offer a n

63 In proliferative vitreoretinopathy (PVR), retinal pigment e

64 the environment that drives RPE responses in proliferative vitreoretinopathy (PVR), suggesting that t

65 l detachment with (n = 7) or without (n = 9) proliferative vitreoretinopathy (PVR), vitreous hemorrha

66 l-thickness macular hole (n = 33), recurrent proliferative vitreoretinopathy (PVR)-related retinal de

67 the repair of retinal detachment related to proliferative vitreoretinopathy (PVR).

68 inal detachment in the context of high-grade proliferative vitreoretinopathy (PVR).

69 n the setting of a blinding condition called proliferative vitreoretinopathy (PVR).

70 mes of vitreoretinal surgery for established proliferative vitreoretinopathy (PVR).

71 proved tyrosine kinase inhibitor, to prevent proliferative vitreoretinopathy (PVR).

72 s age-related macular degeneration (AMD) and proliferative vitreoretinopathy (PVR).

73 bility of fibroblasts to induce experimental proliferative vitreoretinopathy (PVR).

74 sponses in the context of in vitro models of proliferative vitreoretinopathy (PVR).

75 BB (PDGF), and to establish its relevance to proliferative vitreoretinopathy (PVR).

76 and inferior breaks, mostly with associated proliferative vitreoretinopathy (PVR).

77 h age-related macular degeneration (AMD) and proliferative vitreoretinopathy (PVR).

78 s age-related macular degeneration (AMD) and proliferative vitreoretinopathy (PVR).

79 tor to fibrotic diseases of the eye, such as proliferative vitreoretinopathy (PVR).

80 development of epiretinal membranes found in proliferative vitreoretinopathy (PVR).

81 antial contribution to the events leading to proliferative vitreoretinopathy (PVR).

82 ated in this investigation were: (1) grade B proliferative vitreoretinopathy (PVR; n = 917), (2) grad

83 io [OR], 7.0), CNV recurrence (OR, 2.6), and proliferative vitreoretinopathy (PVR; OR, 17.6) were sta

84 This intraocular fibrosis, known as proliferative vitreoretinopathy, results in a blinding t

85 patients with retinal detachment (3.65) and proliferative vitreoretinopathy stages A, B, and C (2.06